| Targeting CDK2 in cancer: challenges and opportunities for therapy S Tadesse, AT Anshabo, N Portman, E Lim, W Tilley, CE Caldon, S Wang Drug discovery today 25 (2), 406-413, 2020 | 195 | 2020 |
| CDK9: a comprehensive review of its biology, and its role as a potential target for anti-cancer agents AT Anshabo, R Milne, S Wang, H Albrecht Frontiers in oncology 11, 678559, 2021 | 86 | 2021 |
| Validation of the amharic version of the brief fatigue inventory for assessment of cancer-related fatigue in Ethiopian cancer patients GT Gebremariam, AT Anshabo, W Tigeneh, E Engidawork Journal of pain and symptom management 56 (2), 264-272, 2018 | 21 | 2018 |
| Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation M Yu, T Teo, Y Yang, M Li, Y Long, S Philip, B Noll, GK Heinemann, ... European Journal of Medicinal Chemistry 214, 113248, 2021 | 14 | 2021 |
| Validation of the Amharic version of the brief pain inventory for utility in Ethiopian Cancer patients AT Anshabo, S Migbaru, D Awoke, W Tigeneh, E Engidawork Pain Practice 17 (8), 1023-1031, 2017 | 12 | 2017 |
| Validation of the amharic version of the MD Anderson symptom inventory and assessment of symptoms in Ethiopian cancer patients AT Anshabo, S Migbaru, A Mulu, D Negusu, AA Asfaw, D Awoke, ... Journal of Pain and Symptom Management 51 (5), 947-953, 2016 | 11 | 2016 |
| An orally bioavailable and highly efficacious inhibitor of cdk9/flt3 for the treatment of acute myeloid leukemia AT Anshabo, L Bantie, S Diab, J Lenjisa, A Kebede, Y Long, ... Cancers 14 (5), 1113, 2022 | 10 | 2022 |
| Assessment of type II diabetes mellitus drug therapy in diabetes clinic of a tertiary care teaching hospital in Addis Ababa AA Asfaw, NM Mamo, AT Anshabo, S Hawaze Archives of Pharmacy Practice Vol 5 (3), 2014 | 5 | 2014 |
| Intra-articular Injection of a B Cell Depletion Antibody Enhances Local Exposure to the Joint-Draining Lymph Node in Mice with Collagen-Induced Arthritis AD Lam, IK Styles, D Senyschyn, E Cao, A Anshabo, M Abdallah, ... Molecular Pharmaceutics 20 (4), 2053-2066, 2023 | 1 | 2023 |
| LS007, a potent and orally bioavailable CDK9 inhibitor, suppresses the growth of triple-negative and estrogen receptor-positive breast cancer MH Rahaman, Y Zhang, MS Islam, G Heinemann, AT Anshabo, ... Cancer Research 79 (13_Supplement), 4427-4427, 2019 | | 2019 |
